ReviewTherapeutic advances in chronic disease2024

The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.

Joseph E McClellan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.